Opus Genetics (IRD) Company Report

Analyst Earnings Quarterly Reports

Earnings summaries and quarterly performance for Opus Genetics.

Research analysts covering Opus Genetics.

Recent press releases and 8-K filings for IRD.

Opus Genetics to Present at J.P. Morgan Healthcare Conference, Provides Pipeline and Financial Updates

IRD

New Projects/Investments

Guidance Update

Opus Genetics, Inc. management will deliver a corporate presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026.
The company's OPGx-BEST1 Phase 1/2 trial dosed its first participant in Q4 2025, with initial data expected in Q1 2026 and 3-month results for Cohort 1 in mid-2026.
For its OPGx-LCA5 program, positive Phase 1/2 safety and efficacy results were observed, and enrollment is ongoing in the run-in period for a planned adaptive Phase 3 trial.
Opus Genetics reported pro-forma cash and equivalents of ~$54 million as of September 30, 2025, including $23 million raised in November 2025, providing an expected funding runway into H2 2027.

Jan 12, 2026, 2:00 PM

Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts

IRD

Guidance Update

New Projects/Investments

Opus Genetics reported cash and cash equivalents of $30.8 million as of September 30, 2025, and subsequently raised $23.0 million in gross proceeds, resulting in a total cash position of over $50 million, which is expected to fund operations into the second half of 2027.
The company anticipates announcing initial clinical data for OPGx-BEST1 in Q1 2026, with 3-month results from Cohort 1 expected in mid-2026.
For OPGx-LCA5, dosing in the pivotal Phase 3 trial is expected in the second half of 2026.
A Supplemental New Drug Application (sNDA) was submitted for Phentolamine Ophthalmic Solution 0.75% for the treatment of presbyopia, with an anticipated regulatory decision by the end of 2026.

Jan 8, 2026, 12:10 PM

Opus Genetics Announces Q3 2025 Financial Results and Pipeline Updates

IRD

Earnings

New Projects/Investments

Guidance Update

Opus Genetics reported a net loss of $17.5 million, or $(0.25) per basic and diluted share, for the third quarter ended September 30, 2025.
As of September 30, 2025, cash and cash equivalents were $30.8 million. Following the quarter, the company raised an additional $23.0 million in gross proceeds from an equity offering, extending its cash runway into the second half of 2027.
The company announced positive 3-month pediatric and 18-month adult clinical data from its OPGx-LCA5 Phase 1/2 trial, and a successful FDA RMAT meeting provides potential for an accelerated regulatory pathway.
The FDA accepted the Investigational New Drug (IND) application for OPGx-BEST1, with recruitment ongoing for its Phase 1/2 trial and initial data expected in the first quarter of 2026. Additionally, a Supplemental New Drug Application (sNDA) submission for Phentolamine Ophthalmic Solution 0.75% is planned by year-end 2025.

Nov 12, 2025, 12:07 PM

Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial

IRD

Opus Genetics announced positive three-month data from the pediatric cohort of its OPGx-LCA5 Phase 1/2 clinical trial for Leber congenital amaurosis type 5 (LCA5).
The OPGx-LCA5 therapy was well tolerated in all six participants (three adults and three pediatric), with no ocular serious adverse events or dose-limiting toxicities observed.
Pediatric participants demonstrated significant improvements in visual function, including a group average of a 0.3 logMAR improvement in visual acuity and greater than one log unit improvement in cone sensitivity.
Durable improvements in visual acuity were sustained through 18 months in adult participants.
The company expects to meet with the FDA in Q4 2025 to discuss the trial results and next steps for the LCA5 program.